Human embryonic stem cells have long been a paradox for scientists. Now a team at a US biotech company is to start the world's first study of a treatment for spinal cord injuries based on them.

California-based Geron Corporation has already gained permission from the US Food and Drug Administration to inject some eight to ten patients, who can use their arms but can't walk, with cells derived from embryonic cells.